<DOC>
	<DOCNO>NCT00401492</DOCNO>
	<brief_summary>The main purpose study describe activity toxicity single-agent gemcitabine give prolonged infusion , two 2-drug combination contain cisplatin ( cisplatin + vinorelbine , cisplatin + gemcitabine ) treatment elderly patient advance non small cell lung cancer</brief_summary>
	<brief_title>MILES-02 : Study Chemotherapy Treatment Toxicity Elderly Patients With Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description>The study design include three parallel phase II study , rule patient selection outcome assessment . In two study cisplatin-based doublet , dose-finding phase plan , subsequent cohort 6 patient treat increase dos cisplatin ( 50-60-70 mg/m² ) . Following phase , patient assign three study randomization procedure , reduce selection bias . Arm A : gemcitabine : Gemcitabine 1200 mg/m2 intravenously 2 hour ( 10 mg/m²/minute ) day 1 &amp; 8 cycle , every 21 day , maximum 6 cycle . Arm B : cisplatin + vinorelbine : Vinorelbine 25 mg/m² day 1 &amp; 8 , follow Cisplatin ( 50 60 70 mg/m² ) day 1 cycle , every 21 day , maximum 6 cycle . Arm C : cisplatin + gemcitabine : Gemcitabine 1000 mg/m2 , , day 1 &amp; 8 , follow Cisplatin ( 50 60 70 mg/m² ) day 1 cycle , every 21 day , maximum 6 cycle .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologic cytologic diagnosis NSCLC Stage IV IIIB pleural effusion metastatic supraclavicular lymphoadenopathy Age &gt; = 70 year . Written informed consent . Performance status ( ECOG ) ³2 Previous chemotherapy . Symptomatic brain metastasis require synchronous radiotherapy Previous radiotherapy ( complete less 4 week enrollment ) Previous synchronous malignant disease ( except adequately treat non melanomatous skin cancer carcinoma situ cervix ) diagnose last five year enrollment . Neutrophils &lt; 2.000/mm³ platelet &lt; 100.000/mm³ hemoglobin &lt; 10 g/dl . Serum creatinine &gt; 1.5 time UNL . GOT and/or GPT &gt; 1.25 time UNL serum total bilirubin &gt; 1.25 time UNL without hepatic metastasis . GOT and/or GPT &gt; 2.5 time UNL serum total bilirubin &gt; 1.5 time UNL hepatic metastasis . Other concomitant disease contraindicate study treatment . Refusal write informed consent . Followup impossible .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>elderly</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>quality life</keyword>
	<keyword>ADL</keyword>
	<keyword>toxicity</keyword>
</DOC>